03/03/2011
Rivaroxaban is a new oral anticoagulant developed by Bayer HealthCare and sold under the trade name Xarelto®. It is a direct factor Xa inhibitor approved for the prevention of VTE after hip or knee replacement surgery in more than 80 countries (except US). Rivaroxaban is expected to be approved for other indications like stroke prevention in patients with atrial fibrillation in the near future. This makes rivaroxaban a future major player in the anticoagulants world.
STA®-Rivaroxaban Calibrator &Control is a new solution for the determination of rivaroxaban concentration when required.
Including rivaroxaban calibrators and controls, this solution can be used with two methods for different clinical needs and laboratory requirements:
Results are expressed in ng/mL of rivaroxaban [1,2].
Reagents are offered with all the standard guarantees:

1. SAMAMA M.M. et al., Rivaroxaban calibrator and control sets measuring rivaroxaban plasma concentrations using prothrombin time, ICT, Milan, Italy, poster, 2010.
2. SAMAMA M.M. et al., Evaluation of the anti-factor Xa chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls, ASH, 5071 b JN04, Abstract, 2010.
Available now.
* For Research Use Only
Contactez-nous | Credits et copyrights | Mentions légales | Plan du site | Liste des produits